Navigation Links
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Date:2/6/2009

r, kidney disorder, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of June 15, 2008 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be gua
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... 30, 2015  Growth of the U.S. nonprescription market ... former prescription users to the OTC market. Due to ... robust Rx-to-OTC switch activity over the next five years ... many new brands entering the market into existing categories. ... five years (even those with low to moderate likelihood), ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Oct. 27 Pharmos Corporation (Pink Sheets: PARS ... nine-month period ended September 30, 2010. These results are included ... been filed with the SEC. During the quarter ... potential partners for Dextofisopam, its drug for irritable bowel syndrome ...
... N.J., Oct. 27 Systech International, innovator of ... Pac Automation, a leading supplier of end-of-line packaging ... integrated solution for global serialization requirements at Pack ... attendees have the opportunity to examine first hand ...
Cached Medicine Technology:Pharmos Corporation Reports 2010 Third Quarter Results 2Pharmos Corporation Reports 2010 Third Quarter Results 3Pharmos Corporation Reports 2010 Third Quarter Results 4Systech and Pester Pac Automation Exhibit Integrated Serialization Solution at Pack Expo 2010 2
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness ... into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... Six Million American Children of Healthcare Services, WASHINGTON, ... Psychiatry strongly urges Congress to override,President Bush,s veto of ... The House passed the S-CHIP bill by a 265-159 ... the President,s veto. The Senate passed the,measure by a ...
... Pam Brady,President of the California State PTA, ... federal legislation to expand the State,Children,s Health Insurance ... morning of legislation to expand the SCHIP,program is ... families,including approximately 800,000 in California, who need medical ...
... cosmetic dentist Dr. William,Hoskyns has joined the Atlanta Center ... Debra Gray King and her team at the Atlanta ... an international,reputation as the dentist to see for porcelain ... for his celebrity and high profile patients, Dr. Hoskyns ...
... JOSE, Calif., Oct. 3 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... Small-Cap Growth,Stock Conference at 10:00 a.m. ET on October ... York, New York. An archive of the VNUS ...
... TORONTO, Oct. 3 /PRNewswire/ - Much controversy has ... potential complications of drug-eluting,heart stents, increasing the risk ... angioplasty procedure. However, a new Canadian study led ... and McMaster University,s Program for Assessment of Technologies ...
... Oct. 3 The American Health Information,Management ... ICD-10,implementation assessment and training consultation services for ... following AHIMA,s signing of,a contract with the ... contract requires AHIMA to determine ICD-10,s,impact(s) on ...
Cached Medicine News:Health News:American Academy of Child and Adolescent Psychiatry Reacts to S-CHIP Veto 2Health News:Prominent Cosmetic Dentist Dr. William Hoskyns Joins Leading Atlanta Practice 2Health News:New Canadian study finds drug coated heart stents to be safe: 2Health News:New Canadian study finds drug coated heart stents to be safe: 3Health News:New Canadian study finds drug coated heart stents to be safe: 4Health News:AHIMA Signs Contract With CMS for ICD-10 Implementation Assessment and Training 2
... IQmark Digital ECG is a highly advanced and ... Windows personal computer. Everything you need to get ... acquisition and operating costs of the IQmark Digital ... stand-alone ECG machines (even including the cost of ...
... medical-grade ingredients and Alpha-Beta and TCA to ... has been used for many years to ... mask of pregnancy and other superficial skin ... or removal of the upper layers of ...
... Cosmedix Blueberry Smoothie is ... the skin with the use ... active blueberry extracts exfoliate the ... glow without visible irritation. This ...
... PCA Peel® formula, this peel will ... exfoliation for oilier, thicker and more ... on extremely sun damaged and thickened ... those with active/cystic acne and asphyxiated ...
Medicine Products: